Uveitis unplugged: systemic therapy
|
|
- Piers Briggs
- 6 years ago
- Views:
Transcription
1 Uveitis unplugged: systemic therapy Hobart 2017 Peter McCluskey Save Sight Institute Sydney Eye Hospital Sydney Medical School University of Sydney Sydney Australia No financial or proprietary interest in any material discussed
2 Disappointing Conflict of Interest Disclosure Peter McCluskey, dreadful golfer ENBREL user
3 Financial Disclosures: Advisory Boards and/or Consultant: - AbbVie - Allergan - Santen - Servier AbbVie & Allergan relevant for today s presentation
4 Principles of treatment similar despite diverse aetiologies treat infectious uveitis with specific antimicrobial therapy + judicious use of corticosteroids & IMT therapy depends on presence cause & severity of a threat to vision specific therapy for non inflammatory complications treat inflammatory visual loss with antiinflammatory drugs
5 Inflammatory causes of vision loss cystoid macular oedema ischaemic retinal vasculitis progressive retinitis/ choroiditis optic neuropathy vitritis severe anterior uveitis Systemic Therapy for Uveitis
6 Principles of treatment topical corticosteroid therapy controls most anterior uveitis CME in > 40% of patients with posterior uveitis CME is a common driver of ocular therapy - usually treat unilateral CME locally - typically treat bilateral disease with systemic therapy - often combine local & systemic therapy (up to 60% in MUST)
7 Local Therapy topical: steroids, NSAIDs, CAIs periocular steroids intravitreal: steroids, avastin, methotrexate, infliximab, sustained release: retisert, ozudex Surgery vitrectomy Systemic Therapy NSAIDs corticoseroids immunosuppressives: methotrexate, cyclosporine, mycophenolate, azathioprine, cyclophosphamide biologics: anti-tnfs, anti-il2, anti-il17, anti-il6, anakinra, anti- CD20, interferons
8 Systemic Therapy systemic steroids gold standard therapy for CME & vision threatening ocular inflammation usually for bilateral disease need sufficient therapy to control inflammation & CME rapid response with high dose steroids, then combination immunotherapy in longer term minimum 6-36 month commitment to therapy
9 Drug Selection Systemic Therapy for Uveitis IMT immunomodulatory therapy - corticosteroids + immunosuppressive drug steroid sparing drugs must get steroids to a safe maintenance dose at least < 7.5mgs per day, preferably 5mgs/day or zero evidence that all steroid sparing drugs effective some drugs more effective for eye disease - methotrexate - mycophenolate
10 commonly used drugs methotrexate mycophenolate azathioprine uncommonly used drugs cyclosporine tacrolimus cyclophosphamide dapsone sulphasalazine biologics interferon 2a monoclonal antibodies - anti-tnf - anti-cd20 - others: anti-il1β, IL6, IL17, IL2, IL12/23, CD52 IVIG
11 IMT: The Sydney Experience Systemic Regimens Drugs 190 systemic therapy mean age (31%) steroids alone 132 (69%) steroids + I/S drug 67/132 (51%) multiple I/S drugs Systemic Therapy for Uveitis methotrexate 69 (52%) mycophenolate 33 (25%) cyclosporine 31 (23%) azathioprine 24 (18%) other drugs 37 (28%) (cyclophosphamide, biologics, salazopyrine) Chang J, Wakefield D, McCluskey PJ. Immunosuppressive therapy in patients with non infectious uveitis ; Unpublished data
12 IMT: The Sydney Experience Systemic Regimens Drugs 190 systemic therapy mean age (31%) steroids alone 132 (69%) steroids + I/S drug 67/132 (51%) multiple I/S drugs Systemic Therapy for Uveitis methotrexate 69 (52%) mycophenolate 33 (25%) cyclosporine 31 (23%) azathioprine 24 (18%) other drugs 37 (28%) (cyclophosphamide, biologics, salazopyrine) Chang J, Wakefield D, McCluskey PJ. Immunosuppressive therapy in patients with non infectious uveitis ; Unpublished data
13 IMT: The Sydney Experience Systemic Regimens Drugs 190 systemic therapy mean age (31%) steroids alone 132 (69%) steroids + I/S drug 67/132 (51%) multiple I/S drugs Systemic Therapy for Uveitis methotrexate 69 (52%) mycophenolate 33 (25%) cyclosporine 31 (23%) azathioprine 24 (18%) other drugs 37 (28%) (cyclophosphamide, biologics, salazopyrine) Chang J, Wakefield D, McCluskey PJ. Immunosuppressive therapy in patients with non infectious uveitis ; Unpublished data
14 IMT: The Sydney Experience Systemic Regimens Drugs 190 systemic therapy mean age (31%) steroids alone 132 (69%) steroids + I/S drug 67/132 (51%) multiple I/S drugs Systemic Therapy for Uveitis methotrexate 69 (52%) mycophenolate 33 (25%) cyclosporine 31 (23%) azathioprine 24 (18%) other drugs 37 (28%) (cyclophosphamide, biologics, salazopyrine) Chang J, Wakefield D, McCluskey PJ. Immunosuppressive therapy in patients with non infectious uveitis ; Unpublished data
15 Joshi J, Talat L, Yaganati S et al. Outcomes of changing immunosuppressive therapy after treatment failure in patients with non infectious uveitis. Ophthalmology 2014; 121:
16 Joshi J, Talat L, Yaganati S et al. Outcomes of changing immunosuppressive therapy after treatment failure in patients with non infectious uveitis. Ophthalmology 2014; 121:
17 Joshi J, Talat L, Yaganati S et al. Outcomes of changing immunosuppressive therapy after treatment failure in patients with non infectious uveitis. Ophthalmology 2014; 121:
18 Joshi J, Talat L, Yaganati S et al. Outcomes of changing immunosuppressive therapy after treatment failure in patients with non infectious uveitis. Ophthalmology 2014; 121:
19 Joshi J, Talat L, Yaganati S et al. Outcomes of changing immunosuppressive therapy after treatment failure in patients with non infectious uveitis. Ophthalmology 2014; 121:
20 Rheumatology Rx 1986 the IMT & biologics revolution Rheumatology Rx 2016 Images courtesy A/Prof Jane Bleasel
21 Uveitis responds to TNF Mab therapy (not etanercept) Not clear where else uveitis fits within this network at this time
22 Biologic therapy Systemic Therapy for Uveitis monoclonal antibodies TNF antibodies effective: sarcoid, JIA, IBD uveitis compelling evidence in Behcets 80% plus response rates no long term remission increasing range of drugs variable experience as most new drugs Yamada Y, Sugita S, Tanaka H et al. Comparison of infliximab versus ciclosporin during the initial 6 month treatment period in Behcet disease. Brit J Ophthalmol 2010; 94:284-88
23 Adalimumab Clinical trials: clinical case series: - several open label studies - retrospective & prospective case series - 38% at 12 weeks; 57% at 1 year % treatment effect across studies - French TNF study 93% at 1 year randomised prospective studies: - VISUAL I active uveitis - VISUAL II inactive uveitis
24 VISUAL I: RCT: active intermediate, posterior or pan uveitis (NINA uveitis) 217 patients steroid sparing effect of adalimumab Vs placebo 1 endpoint: time to treatment failure multiple endpoints for Rx failure: AC cells, vitreous flare, new lesions, >15 letter V/A loss, OCT CMT Jaffe G, Dick A, Brezin A et al. Adalimumab in patients with active non infectious uveitis. NEJM 2016; 375:
25 Jaffe G, Dick A, Brezin A et al. Adalimumab in patients with active non infectious uveitis. NEJM 2016; 375:
26 Jaffe G, Dick A, Brezin A et al. Adalimumab in patients with active non infectious uveitis. NEJM 2016; 375:
27 early and sustained uveitis control 50% increase in time to treatment failure Jaffe G, Dick A, Brezin A et al. Adalimumab in patients with active non infectious uveitis. NEJM 2016; 375:
28 VISUAL I: significant Rx effect across multiple endpoints no difference in time to OCT macular oedema Jaffe G, Dick A, Brezin A et al. Adalimumab in patients with active non infectious uveitis. NEJM 2016; 375:
29 Uveitic Macular Oedema
30 Uveitic Macular Oedema
31 VISUAL II: RCT: inactive intermediate, posterior or pan uveitis (NINA uveitis) 229 patients steroid sparing effect of adalimumab Vs placebo 1 endpoint: time to treatment failure multiple endpoints for Rx failure: AC cells, vitreous flare, new lesions, >15 letter V/A loss, OCT CMT Nguyen Q, Merrel P, Jaffe G et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016; epub August 16
32 Nguyen Q, Merrel P, Jaffe G et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016; epub August 16
33 Nguyen Q, Merrel P, Jaffe G et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016; epub August 16
34 early and sustained uveitis control statistically significant increase in time to treatment failure Nguyen Q, Merrel P, Jaffe G et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016; epub August 16
35 VISUAL I & II: drug safety > 10 years of adalimumab use in other diseases side effects: - injection site reactions - infection no new safety signals esp malignancy & infection must exclude latent TB intermediate uveitis: must have MRI to exclude demyelinating disorder
36 Biologics for eye disease: early Sydney experience Behcet s 6 interferon 1 poor responder JIA uveitis 11 adalimumab 8 infliximab 3 3 poor responders => multiple TNFs + IL-6 SpA + RAAU/CAU 13 adalimumab 1 poor responder => multiple TNFs sarcoid uveitis 2 adalimumab scleritis 3 adalimumab 1 infliximab 1 rituximab 1 36
37 Use of adalimumab in non-infectious uveitis: real world data Jonathan T Lee, William Yates, Sophie Rogers, Peter McCluskey, Lyndell L Lim
38 mg/day Systemic Therapy for Uveitis Mean Prednisolone dose Active at baseline n = 13 patients Inactive at baseline n = 9 patients Follow-up
39 Failure rate Failure rate Failure rate Failure rate Systemic Therapy for Uveitis Time to Treatment Failure Active at baseline Inactive at baseline Active eyes Inactive eyes Number at risk Weeks Number at risk Weeks Median TTF: 21 weeks VISUAL I: 24 weeks Median TTF: <50% failed VISUAL II: <50% failed
40 The challenge TNF blockers are very useful therapy for patients with vision threatening uveitis often challenging co-morbidities Ophthalmologists do not have the skills to manage patients on TNF blockers in isolation significant potential for systemic complications will require new team management paradigm 40
41 Who does what: The team approach Ophthalmologist Physician Is it working? I/S Drug is it causing side effects?
42 The challenge when are biologics contra-indicated???? - infective uveitis - demyelinating disease - infective co-morbidities what are the risks????? - infection - latent TB - demyelinating disease in IU patients - non lethal malignancy 42
43 Emerging Treatment Paradigm relapse relapse systemic steroids + methotrexate / mycophenolate / azathioprine aim to taper & stop oral steroids change to / add biologic consider local therapy + systemic therapy No one should go blind without a dose of intravitreal triamcinolone 43
44 Take Home Messages: long term commitment by both patient and ophthalmologist get help team approach for systemic therapy defining role of biologics about to start biologics revolution in uveitis
Regional vs. Systemic Therapy. Corticosteroids. Regional vs. Systemic Therapy for Uveitis. Considerations
Regional vs. Systemic Therapy for Uveitis Nisha Acharya,, M.D., M.S. Director, Uveitis Service F.I. Proctor Foundation University of California, San Francisco December 4, 2010 No financial disclosures
More informationAdalimumab and dexamethasone for treating non-infectious uveitis [ID763]
Adalimumab and dexamethasone for treating non-infectious uveitis [ID763] Multiple Technology Appraisal 2 nd meeting: 12 th April 2017 Committee C Slides for Committee, projector and public [NoACIC] 1 The
More informationSurgery in patients with uveitis. Lyndell Lim and Anthony Hall
Surgery in patients with uveitis Lyndell Lim and Anthony Hall Disclosures Off label treatments Paid advisory board Bayer Paid research support Allergan (makers of Ozurdex) Paid research support B and L
More informationNausheen Khuddus, MD Melissa Elder, MD, PhD
Nausheen Khuddus, MD Melissa Elder, MD, PhD Nausheen Khuddus, MD Pediatric Ophthalmologist and Strabismus Specialist Accent Physicians Gainesville, Florida What Is Uveitis? Uveitis is caused by inflammatory
More informationMoncef Khairallah, MD
Moncef Khairallah, MD Department of Ophthalmology, Fattouma Bourguiba University Hospital Faculty of Medicine, University of Monastir Monastir, Tunisia INTRODUCTION IU: anatomic form of uveitis involving
More informationNew Drugs for Uveitis. Medical Eye Unit St Thomas Hospital
New Drugs for Uveitis Miles Stanford Medical Eye Unit St Thomas Hospital x Epithelium x x Antigen Y Y Y Y IgG m cd4 IL-2 Y m + IL-12 Cytotoxic T B pmn Ig s PG s. LTB4 O - IL-6 TNFα IFNγγ IL-2 Th1 IL-10
More informationAbbreviated Drug Evaluation: Fluocinolone acetonide intravitreal implant (Retisert )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationInterim Clinical Commissioning Policy Statement: Adalimumab for Severe Refractory Uveitis. Reference: NHS England: /PS
Interim Clinical Commissioning Policy Statement: Adalimumab for Severe Refractory Uveitis Reference: NHS England: 170010/PS Publications Gateway Reference: Document Purpose Policy 05527s Document Name
More informationOphthalmology Subcommittee of PTAC Meeting held 30 October (minutes for web publishing)
Ophthalmology Subcommittee of PTAC Meeting held 30 October 2014 (minutes for web publishing) Ophthalmology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationEvolving therapies for posterior uveitis. Infliximab (Remicade) Infliximab: pharmacology. FDA-approved monoclonal antibody therapy Target
Evolving therapies for posterior uveitis Sam Dahr, M.D. September 17, 2005 Midwest Ophthalmology Conference Infliximab (Remicade) FDA approved for Crohn s disease, rheumatoid arthritis, and psoriatic arthritis
More informationUveitis literature 2014: the year in review. Russell N. Van Gelder, MD, PhD Department of Ophthalmology University of Washington Seattle, WA
Uveitis literature 2014: the year in review Russell N. Van Gelder, MD, PhD Department of Ophthalmology University of Washington Seattle, WA Disclosures RVG serves as Associate Editor of IOVS Editorial
More informationMultiple Technology Appraisal (MTA) Adalimumab, dexamethasone and sirolimus for treating non-infectious uveitis
Multiple Technology Appraisal (MTA) Adalimumab, dexamethasone and sirolimus for treating non-infectious Response to consultee and commentator comments on the draft remit and draft scope (post-referral)
More informationTechnology appraisal guidance Published: 26 July 2017 nice.org.uk/guidance/ta460
Adalimumab and dexamethasone for treating non-infectious uveitis Technology appraisal guidance Published: 26 July 2017 nice.org.uk/guidance/ta460 NICE 2017. All rights reserved. Subject to Notice of rights
More informationUpdate on management of Anterior Uveitis
Update on management of Anterior Uveitis Parthopratim Dutta Majumder Senior Consultant, Department of Uvea & Intraocular Inflammation Medical Research Foundation, Sankara Nethralaya ABCD of Treating a
More informationMethotrexate for uveitis associated with juvenile idiopathic arthritis: Value and requirement for additional anti-inflammatory medication
European Journal of Ophthalmology / Vol. 17 no. 5, 2007 / pp. 743-748 Methotrexate for uveitis associated with juvenile idiopathic arthritis: Value and requirement for additional anti-inflammatory medication
More informationAdalimumab in Noninfectious Uveitis of Idiopathic Etiology Efficacy Across Different Anatomical Locations the VISUAL I and VISUAL II Trials
9:00 AM Adalimumab in Noninfectious Uveitis of Idiopathic Etiology Efficacy Across Different Anatomical Locations the VISUAL I and VISUAL II Trials Pauline T. Merrill, MD Albert T. Vitale, MD Eric Fortin,
More informationNoninfectious Posterior Uveitis: The Rationale for Steroid Use
Insert to October 2016 CME Activity Noninfectious Posterior Uveitis: The Rationale for Steroid Use Thomas Albini, MD, moderator Nisha Acharya, MD Phoebe Lin, MD, PhD Quan Dong Nguyen, MD, MSc Steven Yeh,
More informationThe Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis
Pediatr Drugs (2015) 17:283 301 DOI 10.1007/s40272-015-0128-2 REVIEW ARTICLE The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis Melissa A. Lerman 1 C. Egla Rabinovich 2 Published
More informationiologic Agents in the Treatment of Non-Infectious Uveitis
What is New B iologic Agents in the Treatment of Non-Infectious Uveitis Amala George DNB The treatment of non-infectious uveitis is a challenge to clinicians. The treatment involves suppressing the deleterious
More informationAPPLICATION FOR SPECIAL AUTHORITY. Subsidy for Infliximab
APPLICATION FOR SPECIAL AUTHORITY Fm SA1778 Subsidy f Infliximab Application Categy Page Graft vs host disease - Initial application... 2 Pulmonary sarcoidosis - Initial application... 2 Previous use -
More informationManagement of uveitis
Management of uveitis DR. ANUPAMA KARANTH Anti-inflammatory agents -itis = inflammation Treatment : stop inflammation Use anti-inflammatory drugs Most potent of such agents : Corticosteroids Corticosteroids
More informationUnderstanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
More informationYou can C-ME after Uveitis
You can C-ME after Uveitis Abstract: Approximately 50% of uveitis patients will present with vision loss secondary to cystoid macular edema[1]. Two patients with uveitis present with a constant decrease
More informationScleritis LEN V KOH OD
Scleritis LEN V KOH OD 2014 PUCO 1 Introduction A painful, destructive, and potentially blinding disorder Highly symptomatic High association with systemic disease Immunosuppresssive agents 2014 PUCO 2
More informationTHE BURDEN OF NONINFECTIOUS UVEITIS OF THE POSTERIOR
THE BURDEN OF NONINFECTIOUS UVEITIS OF THE POSTERIOR SEGMENT: A REVIEW New pharmacologic treatment options are urgently needed. BY STEVEN YEH, MD, and JESSICA G. SHANTHA, MD Noninfectious uveitis (NIU)
More informationUveitis and treatments; What's new?
Uveitis and treatments; What's new? M Usman Saeed MBBS, MRCOphth, MRCS, FRCOphth (London),FRCS ( Edinburgh) Consultant Ophthalmologist, Epsom and St Helier NHS Trust Carshalton, London www.londoneyedoctors.co.uk
More informationFor the PSV-FAI-001 Study Investigators
An Injectable Fluocinolone Acetonide Insert Decreases the Incidence of Recurrence in Patients with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye: 12 Month Results Glenn J. Jaffe,
More informationHumira. (adalimumab) Drug Update Slideshow NEW INDICATION
Humira (adalimumab) NEW INDICATION Drug Update Slideshow Introduction Brand name: Humira Generic name: Adalimumab Pharmacological class: Tumor necrosis factor (TNF) blocker Strength and Formulation: 10mg/0.2mL,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 September 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 September 2012 OZURDEX 700 micrograms, intravitreal implant in applicator Box of 1 sachet with applicator (CIP:
More informationIntravitreal Triamcinolone Acetonide for Macular Edema in HLA-B27 Negative Ankylosing Spondylitis
105 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationInterim Clinical Commissioning Policy: Adalimumab for Children with Severe Refractory Uveitis
Interim Clinical Commissioning Policy: Adalimumab for Children with Severe Refractory Uveitis Reference: D12X02 NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients
More informationCLINICAL SCIENCES. Antineutrophil Cytoplasmic Antibody Associated Active Scleritis
CLINICAL SCIENCES Antineutrophil Cytoplasmic Antibody Associated Active Scleritis Lani T. Hoang, MD; Lyndell L. Lim, MBBS, FRANZCO; Brian Vaillant, MD; Dongseok Choi, PhD; James T. Rosenbaum, MD Objective:
More information4. Behçet s - Treatment
Registered Charity No: 326679 Caring for those with a rare, complex and lifelong disease www.behcets.org.uk 4. Behçet s - Treatment Introduction Because Behçet s Syndrome/Disease is a multisystem disorder,
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationo White dot syndromes pattern recognition o Activity and damage o Quality of life o Key points o Idiopathic o Sarcoidosis o Multiple sclerosis
Introduction Clinical Assessment of Posterior Uveitis Philip I. Murray Centre for Translational Inflammation Research University of Birmingham Birmingham and Midland Eye Centre o Classification of uveitis
More informationCombined Infliximab and Rituximab in Necrotising Scleritis
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article
More informationThe effect of a single intravitreal implantation of dexamethasone on the fellow eye in bilateral non-infectious uveitis case report
European Review for Medical and Pharmacological Sciences The effect of a single intravitreal implantation of dexamethasone on the fellow eye in bilateral non-infectious uveitis case report J. CISZEWSKA,
More informationInfliximab for the treatment of refractory scleritis
1 Massachussets Eye Research and Surgery Institution, Cambridge, Massachusetts, USA 2 BayView Clinic, Mumbai, India 3 Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA 4 Brigham
More informationWAEPS Medical Personnel Conference March 20, Deanne M. Nakamoto, MD Achieve Eye and Laser Specialists Silverdale, WA
WAEPS Medical Personnel Conference March 20, 2015 Deanne M. Nakamoto, MD Achieve Eye and Laser Specialists Silverdale, WA Up to half of UVEITIS pa/ents have GLAUCOMA. What is uvei/s? Why should we care?
More informationA comprehensive review of mtor-inhibiting pharmacotherapy for the treatment of noninfectious
A comprehensive review of mtor-inhibiting pharmacotherapy for the treatment of noninfectious uveitis Blair, J; Barry, Robert; Moore, David; Denniston, Alastair DOI: 10.2174/1381612823666170111125550 Document
More informationREFRESHER: ANTERIOR UVEITIS
REFRESHER: ANTERIOR UVEITIS 2. SAoO Kongress 28.2.2018 Messe Luzern Dr. med. Christian Böni Augenklinik Universitätsspital Zürich Christian Böni Seite 1 Anterior Uveitis: Clinical Issues Diagnostics: yes
More informationWhat prescribers need to know
HUMIRA Citrate-free presentations in an Electronic Medical Record (EMR) What prescribers need to know 2 / This is your guide to identifying HUMIRA Citrate-free presentations in your Electronic Medical
More informationOriginal Effective Date: 12/13/2017. Subject: Intravitreal corticosteroid implants: Retisert (fluocinolone acetonide intravitreal implant)
Subject: Intravitreal corticosteroid implants: Retisert (fluocinolone acetonide intravitreal implant) Policy Number: MCP-302 Original Effective Date: 12/13/2017 Revision Date(s): Review Date: DISCLAIMER
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More information5. National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS
Alemtuzumab-induced remission of multiple sclerosis-associated uveitis Mark D Willis, 1,2 Trevor P Pickersgill, 2 Neil P Robertson, 1,2 Richard WJ Lee, 3,4,5 Andrew D Dick 3,4,5 & Ester Carreño 3 1. Institute
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationUveitis. Pt Info Brochure. Q: What is Uvea?
Pt Info Brochure Uveitis Q: What is Uvea? A: Uvea is the middle layer of the eye. It is the most vascular structure of the eye. It provides nutrition to the other parts of the eye. The uvea is made up
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
More informationSerge Bourgault 1,2*, Maryam Aroichane 3, Leah A Wittenberg 1, Andréane Lavallée 1,2 and Patrick E Ma 1
Bourgault et al. Journal of Ophthalmic Inflammation and Infection 2013, 3:61 BRIEF REPORT Open Access Treatment of refractory uveitic macular edema with dexamethasone intravitreal implants in a pediatric
More informationHumira (adalimumab) DRUG.00002
Humira (adalimumab) DRUG.00002 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Humira 10 mg/0.2 ml syringe Humira pediatric Crohn s Disease starter pack 40 mg/0.8 ml
More informationAmjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65
Market DC Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2
More informationTREATMENT OF ANCA-ASSOCIATED VASCULITIS
TREATMENT OF ANCA-ASSOCIATED VASCULITIS Loïc Guillevin Hôpital Cochin, Université Paris Descartes Cours DU, 11 mars 2016 1 Disclosure of interest regarding this presentation Roche has provided, in part,
More informationReport on the Deliberation Results
Report on the Deliberation Results September 14, 216 Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau Ministry of Health, Labour and Welfare Brand Name (a) Humira
More informationChoroidal Neovascularization in Sympathetic Ophthalmia
Choroidal Neovascularization in Sympathetic Ophthalmia Lucia Sobrin, Miguel Cordero Coma, C. Stephen Foster Case Report A 49-year-old man presented after a ruptured globe repair of his left eye status
More informationPrior Authorization Policy
Prior Authorization Policy http://www.paramounthealthcare.com/providers Enbrel (etanercept) Pharmacy Benefit Commercial HMO/PPO/CDHP Setting Self-administered subcutaneous injection Medical Benefit N/A
More informationEmerging therapies for the treatment of uveitis: clinical trial observations
Review: Clinical Trial Outcomes Emerging therapies for the treatment of uveitis: clinical trial observations Clin. Invest. (2013) 3(10), 951 966 Uveitis, a leading cause of blindness in the USA and western
More information2.0 Synopsis. Adalimumab M Clinical Study Report R&D/14/0730. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationof Systemic Immunosuppression for Autoimmune Uveitis.
Review of Systemic Immunosuppression for Autoimmune Uveitis The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Castiblanco,
More informationUniversity of Bristol - Explore Bristol Research
Hawkins, M. J., Dick, A. D., Lee, R. W. J., Ramanan, A. V., Carreño, E., Guly, C., & Ross, A. H. (2016). Managing juvenile idiopathic arthritisassociated uveitis. Survey of Ophthalmology, 61(2), 197-210.
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More informationBilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab
Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab Arjun B. Sood, Emory University Gokul Kumar, Emory University Joshua Robinson, Emory University Journal Title: Journal
More informationInflammatory bowel disease (IBD) Overview of the Paediatric investigation plans. Presented by: Richard Veselý. An agency of the European Union
Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans Presented by: Richard Veselý An agency of the European Union Adalimumab - Crohn s disease Indication: Treatment of severe,
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationEffective Health Care Program
Comparative Effectiveness Review Number 28 Effective Health Care Program Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) Executive Summary Background
More informationUveitis is a common cause of preventable blindness
Treatment of Uveitic Cystoid Macular Edema Three case reports discuss the management of inflammatory CME. BY PRANJAL THAKURIA, MD; AND C. STEPHEN FOSTER, MD Uveitis is a common cause of preventable blindness
More informationCOVER FOCUS AT A GLANCE. BY ANDREA ARRIOLA LÓPEZ, MD, MSc, and THOMAS ALBINI, MD
THERAPEUTIC OPTIONS FOR UVEITIS Thanks to a plentiful number of choices available and in the pipeline, the future looks promising for patients with this condition. BY ANDREA ARRIOLA LÓPEZ, MD, MSc, and
More informationHLA-B27-related anterior Uveitis
HLA-B27-related anterior Uveitis Nicholas Jones Manchester Uveitis Clinic The Royal Eye Hospital Manchester Anterior means anterior only IUSG classification: Anterior uveitis = Iris & pars plicata AU
More informationISPUB.COM. An Atypical Presentation of Posterior Scleritis. A Ramanathan, A Gaur CASE REPORT
ISPUB.COM The Internet Journal of Ophthalmology and Visual Science Volume 8 Number 2 A Ramanathan, A Gaur Citation A Ramanathan, A Gaur.. The Internet Journal of Ophthalmology and Visual Science. 2009
More informationImaging in uveitis. Anthony Hall
Imaging in uveitis Anthony Hall Causes of Vision Loss in Uveitis 1. Cystoid macular oedema 26% 2. Cataract 19% 3. Glaucoma 11% 4. Permanent macular damage 5% Rothova et al BJO 1996; 80: 332-336 Macular
More informationPatterns of uveitis in a Philippine eye clinic
VOL. NO. PHILIPPINE JOURNAL OF Ophthalmology JANUARY ORIGINAL ARTICLE - MARCH 5 Harvey S. Uy, MD Irene W. Tam, OD Asian Eye Institute Makati, Philippines Patterns of uveitis in a Philippine eye clinic
More informationOphthalmology. Juliette Stenz, MD
Ophthalmology Juliette Stenz, MD Required Slide Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT Required Slide At the end of this session, students will be able to: 1.
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If
More informationCase 1 History. William Tremaine, M.D. CP
Extraintestinal Manifestations of IBD Case Studies William Tremaine, M.D. Case 1 History 18 year-old woman with Crohn s disease Onset at age 5: colonic & perianal Sulfasalazine, prednisone, mercaptopurine
More informationClinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet s Disease
Case Report http://dx.doi.org/10.3349/ymj.2015.56.4.1158 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 56(4):1158-1162, 2015 Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis
More informationPaediatric rheumatology. Epidemiology of uveitis in children over a 10-year period
Paediatric rheumatology Epidemiology of uveitis in children over a 10-year period L.A.L. Clarke 1, Y. Guex-Crosier 2, M. Hofer 1 1 Immunoallergology and Rheumatology Unit, Department of Paediatrics (DMCP),
More informationYear In Review: VasculitisPers. Disclosures. Learning Objectives. none 4/16/2018. Describe new medications for the treatment of vasculitis
Year In Review: VasculitisPers Cailin Sibley, M.D., M.H.S. Director, Vasculitis Clinic April 27 th, 2018 NTEREST DISCLOSURE Disclosures none Learning Objectives Describe new medications for the treatment
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #270: Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationClinical Commissioning Policy Proposition: Tocilizumab for Giant cell arteritis (adults)
Clinical Commissioning Policy Proposition: Tocilizumab for Giant cell arteritis (adults) Version Number: NHS England A13X12/01 Information Reader Box (IRB) to be inserted on inside front cover for documents
More informationDouble trouble: a patient with both HLA-B27 anterior uveitis and HLA-A29 birdshot chorioretinitis
Haddad and Reddy Journal of Ophthalmic Inflammation and Infection 2014, 4:28 BRIEF REPORT Open Access Double trouble: a patient with both HLA-B27 anterior uveitis and HLA-A29 birdshot chorioretinitis Zeina
More informationUse of Steroids and Immunosuppressive Drugs in the Management of Posterior Uveitis
Eye (1991) 5, 294--298 Use of Steroids and Immunosuppressive Drugs in the Management of Posterior Uveitis SUSAN LlGHTMAN London Summary Posterior uveitis can occur in all age-groups and often has devastating
More informationOCCASIONAL COMMUNICATIONS
UVEITIS: DIAGNOSIS AND MANAGEMENT T. Akerele and S. Lightman, Department of Clinical Ophthalmology, Institute of Ophthalmology, London and Moorfields Eye Hospital, London Uveitis is a generic term which
More informationCOVER FOCUS AT A GLANCE. BY LISA J. FAIA, MD, and KIMBERLY A. DRENSER, MD, PhD
PEDIATRIC UVEITIS: CHALLENGING FOR OPHTHALMOLOGISTS, PATIENTS, AND PARENTS Management of these complicated diseases differs between pediatric and adult patient populations. BY LISA J. FAIA, MD, and KIMBERLY
More informationClinical Features and Prognosis of HLA-B27 Positive and Negative Anterior Uveitis in a Korean Population
J Korean Med Sci 2009; 24: 722-8 ISSN 1011-8934 DOI: 10.3346/jkms.2009.24.4.722 Copyright The Korean Academy of Medical Sciences Clinical Features and Prognosis of HLA-B27 Positive and Negative Anterior
More informationLoss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis
Rheumatology 08;47:10 14 Advance Access publication 1 August 08 doi:10.1093/rheumatology/ken298 Concise Report Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis
More informationUNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS
UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS CanVasc meeting Montreal Nov 22 2012 Patrick Liang Service de rhumatologie Centre Hospitalier Universitaire
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationPharmacy Management Drug Policy
SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes
More informationOptometric Postoperative Cataract Surgery Management
Financial Disclosures Optometric Postoperative Cataract Surgery Management David Dinh, OD Oak Cliff Eye Clinic Dallas Eye Consultants March 10, 2015 Comanagement Joint cooperation between two or more specialists
More informationTreatment Options for Refractory Urticaria
Treatment Options for Refractory Urticaria David A. Khan, MD Professor of Medicine Allergy & Immunology Program Director Division of Allergy & Immunology University of Texas Southwestern Medical Center
More informationBIOLOGICS: A NEW HOPE. Alastair Denniston, University Hospitals Birmingham NHSFT & University of Birmingham
BIOLOGICS: A NEW HOPE Alastair Denniston, University Hospitals Birmingham NHSFT & University of Birmingham And beyond... Biologics in Uvei
More informationAmjevita (adalimumab-atto)
*- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled
More informationUveitis / Iritis. Introduction. Other formats
Other formats Introduction Uveitis / Iritis If you need this information in another format such as audio tape or computer disk, Braille, large print, high contrast, British Sign Language or translated
More informationGlaucoma & Inflammation. Jorge L. Fernandez Bahamonde, MD.
Glaucoma & Inflammation. Jorge L. Fernandez Bahamonde, MD. Definition. Inflammatory ocular conditions compromise outflow of aqueous humor. Keratitis Episcleritis. Scleritis. Uveitis Glaucoma & Keratitis.
More informationNguyen et al. Journal of Ophthalmic Inflammation and Infection 2013, 3:32
Nguyen et al. Journal of Ophthalmic Inflammation and Infection 2013, 3:32 ORIGINAL RESEARCH Open Access Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients
More informationCME in the Phaco era Myth or Reality. Nicholas Lee Hillingdon & Western Eye
CME in the Phaco era Myth or Reality Nicholas Lee Hillingdon & Western Eye Scope History Incidence Pathogenesis Treatments None Steroids Acular Yellox Diamox Anti-vegf Prevention Audit Irvine Gass Syndrome
More information13. Behçet s - In Children
Registered Charity No: 326679 Caring for those with a rare, complex and lifelong disease www.behcets.org.uk 13. Behçet s - In Children How are children affected by Behçet s disease? Behçet s disease (also
More information